UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
(Address of Principal Executive Offices; Zip Code)
Registrant’s Telephone Number, Including Area Code: +
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading |
Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 8.01 | Other Events. |
Sanction of Scheme of Arrangement
At a hearing held on January 22, 2024, the High Court of Justice of England and Wales sanctioned the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 providing for the proposed acquisition (the “Transaction”) of Orchard Therapeutics plc (the “Company”) by Kyowa Kirin International plc, a wholly owned subsidiary of Kyowa Kirin Co., Ltd., a Japanese joint stock company. The scheme of arrangement will become effective upon delivery of the High Court’s order which sanctioned the scheme of arrangement to the Registrar of Companies in England and Wales, which delivery the Company expects to occur on January 24, 2024, and upon which the Transaction will have closed.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ORCHARD THERAPEUTICS PLC | ||||||
| Date: January 22, 2024 | By: | /s/ Frank E. Thomas | ||||
| Frank E. Thomas | ||||||
| President and Chief Operating Officer | ||||||
Document and Entity Information |
Jan. 22, 2024 |
|---|---|
| Cover [Abstract] | |
| Document Type | 8-K |
| Document Period End Date | Jan. 22, 2024 |
| Entity Registrant Name | ORCHARD THERAPEUTICS PLC |
| Entity Incorporation State Country Code | X0 |
| Entity File Number | 001-38722 |
| Entity Tax Identification Number | 00-0000000 |
| Entity Address Address Line 1 | 245 Hammersmith Road |
| Entity Address City Or Town | London |
| Entity Address Postal Zip Code | W6 8PW |
| Entity Address Country | GB |
| Country Region | 44 |
| City Area Code | (0) 203 |
| Local Phone Number | 808 8286 |
| Written Communications | false |
| Soliciting Material | false |
| Pre Commencement Tender Offer | false |
| Pre Commencement Issuer Tender Offer | false |
| Security 12b Title | American Depositary Shares, each representing ten ordinary shares, nominal value £0.10 per share |
| Trading Symbol | ORTX |
| Security Exchange Name | NASDAQ |
| Entity Emerging Growth Company | false |
| Amendment Flag | false |
| Entity Central Index Key | 0001748907 |
-8?20$3;8T.P6BP^0"X99K>]9!:G